Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medistim ASAFRA:MD1 +1.00%100 5-Year Yield-on-Cost % is 7.86 as of Jul. 28, 2026, which is 69% above its 10-year median of 4.66. GuruFocus rates FRA:MD1 with a GF Score™ of 100/100 and a GF Value™ of €23.22 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 323 Medical Devices & Instruments companies, Medistim ASA ranks better than 85.45% on this metric.
Medistim ASA's yield on cost for the quarter that ended in Mar. 2026 was 7.86.
The historical rank and industry rank for Medistim ASA's 5-Year Yield-on-Cost % or its related term are showing as below:
FRA:MD1'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 1.71 Med: 4.66 Max: 7.86
Current: 7.86
During the past 13 years, Medistim ASA's highest Yield on Cost was 7.86. The lowest was 1.71. And the median was 4.66.
FRA:MD1's 5-Year Yield-on-Cost % is ranked better than 85.45% of 323
companies
in the Medical Devices & Instruments industry
Industry Median: 2.51
vs FRA:MD1: 7.86
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Medistim ASA 5-Year Yield-on-Cost % Related Terms
FRA:MD1 vs ABT, SYK, MDT: 5-Year Yield-on-Cost % Comparison
For the Medical Devices subindustry, Medistim ASA's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medistim ASA 5-Year Yield-on-Cost % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Medistim ASA's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Medistim ASA's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Therefore, Yield-on-Cost of Medistim ASA is calculated as
Medistim ASA (FRA:MD1) has a 5-Year Yield-on-Cost % of 7.86 as of Jul. 28, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Medistim ASA and its competitors. This is 69% above median its historical median of 4.66. Over the past decade, Medistim ASA's 5-Year Yield-on-Cost % has ranged from 1.71 to 7.86. According to the industry distribution chart, Medistim ASA ranks #47 out of 323 companies in the Medical Devices & Instruments industry, placing it in the top 14.6%.
Is Medistim ASA's 5-Year Yield-on-Cost % too high?
Medistim ASA's current 5-Year Yield-on-Cost % of 7.86 is 69% above median its 10-year median of 4.66. Over the past 10 years, this metric has ranged from a low of 1.71 to a high of 7.86. The Medical Devices & Instruments industry median 5-Year Yield-on-Cost % is 2.51. Medistim ASA's value of 7.86 is 213.1% above this industry median. Based on the distribution chart, Medistim ASA ranks #47 out of 323 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Medistim ASA has a GF Score™ of 100/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Medistim ASA's 5-Year Yield-on-Cost % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Medistim ASA ranks #47 out of 323 companies for 5-Year Yield-on-Cost %. This places Medistim ASA in the top 15% of its industry — outperforming the majority of peers. The industry median 5-Year Yield-on-Cost % is 2.51. Medistim ASA's value of 7.86 is 213.1% above this benchmark. Historically, Medistim ASA's own 5-Year Yield-on-Cost % has ranged from 1.71 to 7.86 over the past decade. While the company's 10-year median is 4.66 vs. the industry median of 2.51, Medistim ASA has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Medical Devices & Instruments company?
The median 5-Year Yield-on-Cost % among Medical Devices & Instruments companies is 2.51, based on 323 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medistim ASA's current 5-Year Yield-on-Cost % of 7.86 is 213.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Medistim ASA and its competitors. For the Medical Devices & Instruments industry, the median 5-Year Yield-on-Cost % is 2.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medistim ASA's current 5-Year Yield-on-Cost % is 7.86, which is 69% above median its own 10-year median of 4.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medistim ASA stock overvalued right now?
Based on GuruFocus' analysis, Medistim ASA (FRA:MD1) is currently considered Modestly Undervalued. The stock's GF Value™ is €23.22, compared to a current price of €20.30 — trading 12.6% below its estimated fair value. The current 5-Year Yield-on-Cost % is 7.86, which is 69% above median its 10-year median of 4.66 and 213.1% above the Medical Devices & Instruments industry median of 2.51. Medistim ASA's overall GF Score™ is 100/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Medistim ASA (FRA:MD1), the current 5-Year Yield-on-Cost % is 7.86 as of Jul. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medistim ASA (FRA:MD1) Overvalued in 2026?
Based on GuruFocus' analysis, Medistim ASA stock appears to be undervalued.
The current stock price of €20.30 is trading 12.6% below its estimated GF Value™ of €23.22.
GuruFocus considers Medistim ASA to be Modestly Undervalued.
Key valuation signals for FRA:MD1:
5-Year Yield-on-Cost %: 7.86 (69% above median its 10-year median of 4.66)
GF Value™: €23.22 vs. price of €20.30 (12.6% below fair value)
Industry Position: 213.1% above the Medical Devices & Instruments median (#47 of 323)
No single metric tells the full story. See the FRA:MD1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medistim ASA is a medical device company. It is engaged in researching, developing, producing, distributing, and sales of medical equipment through its own business or participation in other companies, as well as related activities. The company's business is focused on cardiac and vascular surgery. The group operates in the USA, Europe, China, and the Rest of the World. The main divisions are sale of own products and sale of third-party products. Sale of own products has two business models, the capital model and the lease model. Third-party products segment sells medical devices from third party manufacturers in Norway, Sweden and Denmark. Key revenue is generated from Own Products segment.
100GF Score
Get the complete analysis for FRA:MD1
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:MD1 has been successfully added to your 
